A video-atlas of levodopa-induced dyskinesia in Parkinson's disease: terminology matters.
Biphasic
DBS
Dyskinesia
Gel
Levodopa
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
13
08
2023
accepted:
15
11
2023
medline:
18
3
2024
pubmed:
21
11
2023
entrez:
21
11
2023
Statut:
ppublish
Résumé
Dyskinesia is a common complication of long-term levodopa therapy in patients with Parkinson's disease (PD), which often worsens the quality of life. It is usually dose-dependent and emerges possibly due to pulsatile stimulation of dopamine receptors. Delineating the pattern of dyskinesia is crucial for determining the most effective therapeutic approach, a task that often presents challenges for numerous neurologists. This article comprehensively describes various patterns of dyskinesia in PD patients and features video demonstration of some of the common forms of dyskinesia. We have used a real case scenario as an example to lead the discussion on the phenomenology, distinguishing features, and management of various types of dyskinesia. A comprehensive literature search was conducted in PubMed using "dyskinesia" as a keyword. The prototype case with videos highlights the differentiating features of dyskinesia along with the treatment strategies. A wide range of descriptive rubrics have been used for certain dyskinesia which are described in detail in this article. The newer types of dyskinesia associated with continuous dopaminergic stimulation in patients with advanced PD and their implications have been described. As there are distinct ways of managing various types of dyskinesia, understanding the phenomenology and chronology of dyskinesia is vital for the optimal management of dyskinetic PD patients. We suggest that dyskinesia should be classified broadly into peak-dose dyskinesia (PDD), biphasic dyskinesia (BD), and OFF-period dystonia. The occurrence of low-dose dyskinesia and complex dyskinesia of continuous dopaminergic treatments should be known to specialists and will require additional studies.
Identifiants
pubmed: 37987930
doi: 10.1007/s10072-023-07209-6
pii: 10.1007/s10072-023-07209-6
doi:
Substances chimiques
Levodopa
46627O600J
Antiparkinson Agents
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1389-1397Informations de copyright
© 2023. Fondazione Società Italiana di Neurologia.
Références
Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE (2018) Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol 84:797–811. https://doi.org/10.1002/ana.25364
doi: 10.1002/ana.25364
pubmed: 30357892
Leta V, Jenner P, Chaudhuri KR, Antonini A (2019) Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update. Expert Opin Drug Saf 18:1203–1218. https://doi.org/10.1080/14740338.2019.1681966
doi: 10.1080/14740338.2019.1681966
pubmed: 31619083
Marano M, Naranian T, di Biase L, Di Santo A, Poon Y-Y, Arca R, Cossu G, Marano P, Di Lazzaro V, Fasano A (2019) Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel. Parkinsonism Relat Disord 69:140–146. https://doi.org/10.1016/j.parkreldis.2019.11.008
doi: 10.1016/j.parkreldis.2019.11.008
pubmed: 31759188
Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (“I-D-I” and “D-I-D-”) in response to l-dopa therapy for Parkinson’s disease. Mayo Clin Proc 52:163–174
pubmed: 839864
Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 59:408–413. https://doi.org/10.1212/WNL.59.3.408
doi: 10.1212/WNL.59.3.408
pubmed: 12177375
McLellan DL, Dean BC (1982) Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide. Br Med J 284:1001–1002. https://doi.org/10.1136/bmj.284.6321.1001
doi: 10.1136/bmj.284.6321.1001
Martinez-Ramirez D, Giugni J, Vedam-Mai V, Shukla AW, Malaty IA, McFarland NR, Rodriguez RL, Foote KD, Okun MS (2014) The “brittle response” to Parkinson’s disease medications: Characterization and response to deep brain stimulation. PLoS ONE 9:e94856. https://doi.org/10.1371/journal.pone.0094856
doi: 10.1371/journal.pone.0094856
pubmed: 24733172
pmcid: 3986256
Yan Y, Li Y, Liu X, Zhang L, Wang L, Chang Y (2020) Analysis of factors associated with brittle response in patients with Parkinson’s disease. Ann Clin Transl Neurol 7:677–682. https://doi.org/10.1002/acn3.51028
doi: 10.1002/acn3.51028
pubmed: 32352220
pmcid: 7261752
Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47:S2-9 discussion S9-11
pubmed: 10762127
Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39:11–19
pubmed: 2685647
Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y (1999) The phenomenology of L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 14(Suppl 1):13–8. http://www.ncbi.nlm.nih.gov/pubmed/10493399 . Accessed 30 Oct 2023
Grötzsch H, Sztajzel R, Burkhard PR (2007) Levodopa-induced ocular dyskinesia in Parkinson’s disease. Eur J Neurol 14:1124–1128. https://doi.org/10.1111/j.1468-1331.2007.01919.x
doi: 10.1111/j.1468-1331.2007.01919.x
pubmed: 17880568
Hametner E, Seppi K, Poewe W (2010) The clinical spectrum of levodopa-induced motor complications. J Neurol 2010:s268–s275. https://doi.org/10.1007/s00415-010-5719-9
doi: 10.1007/s00415-010-5719-9
Aquino CC, Fox SH (2015) Clinical spectrum of levodopa-induced complications. Mov Disord 30:8–9. https://doi.org/10.1002/mds.26125
doi: 10.1002/mds.26125
Ramírez-Gómez CC, Zúñiga-Ramírez C, Contartese ML, Montilla V, Gramajo J, Micheli F (2019) Blepharospasm as a manifestation of peak of dose dyskinesia in Parkinson disease. Clin Neuropharmacol 42:14–16. https://doi.org/10.1097/WNF.0000000000000316
doi: 10.1097/WNF.0000000000000316
pubmed: 30649026
Durif F, Vidailhet M, Debilly B, Agid Y (1999) Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord 14:242–245
doi: 10.1002/1531-8257(199903)14:2<242::AID-MDS1007>3.0.CO;2-W
pubmed: 10091616
Rice JE, Antic R, Thompson PD (2002) Disordered respiration as a levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord 17:524–527. https://doi.org/10.1002/mds.10072
doi: 10.1002/mds.10072
pubmed: 12112201
Oyama G, Foote KD, Iyer SS, Zeilman P, Hwynn N, Jacobson CE, Malaty IA, Fernandez HH, Rodriguez RL, Okun MS (2011) Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in parkinson disease. Neurologist 17:282–285. https://doi.org/10.1097/NRL.0b013e318217367b
doi: 10.1097/NRL.0b013e318217367b
pubmed: 21881473
van de Wetering VA, van Dongen, Espay AJ, Marsili L, Sturchio A, Ten Holter S, Bloem BR, Nijkrake MJ (2021) Biphasic (subtherapeutic) levodopa-induced respiratory dysfunction in parkinson disease. Neurol Clin Pract 11:e402–e406. https://doi.org/10.1212/cpj.0000000000001043
doi: 10.1212/cpj.0000000000001043
Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA (2009) Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson’s disease: A double blind video-based analysis. Mov Disord 24:336–343. https://doi.org/10.1002/mds.22208
doi: 10.1002/mds.22208
pubmed: 19006186
Graff-Radford J, Foote KD, Rodriguez RL, Fernandez HH, Hauser RA, Sudhyadhom A, Rosado CA, Sanchez JC, Okun MS (2006) Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Arch Neurol 63:1181–1184. https://doi.org/10.1001/archneur.63.8.1181
doi: 10.1001/archneur.63.8.1181
pubmed: 16908749
Zimmerman TR, Sage JI, Lang AE, Mark MH (1994) Severe evening dyskinesias in advanced Parkinson’s disease: clinical description, relation to plasma levodopa, and treatment. Mov Disord 9:173–177. https://doi.org/10.1002/mds.870090208
doi: 10.1002/mds.870090208
pubmed: 8196678
Marsden CD, Parkes JD, Quinn N (1981) Fluctuations of disability in Parkinson’s disease – clinical aspects. In: Movement Disorders. Elsevier, pp 96–122. https://doi.org/10.1016/B978-0-407-02295-9.50012-6
Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson’s disease: Clinical manifestations. Mov Disord 20:S11–S16. https://doi.org/10.1002/mds.20458
doi: 10.1002/mds.20458
pubmed: 15822109
Marconi R, Lefebvre-Caparros D, Bonnet A-M, Vidailhet M, Dubois B, Agid Y (1994) Levodopa-induced dyskinesias in Parkinson’s disease phenomenology and pathophysiology. Mov Disord 9:2–12. https://doi.org/10.1002/mds.870090103
doi: 10.1002/mds.870090103
pubmed: 8139601
Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301
doi: 10.1093/brain/114.5.2283
pubmed: 1933245
Espay AJ, Fasano A, van Nuenen BFL, Payne MM, Snijders AH, Bloem BR (2012) “On” state freezing of gait in Parkinson disease: A paradoxical levodopa-induced complication. Neurology 78:454–457. https://doi.org/10.1212/WNL.0b013e3182477ec0
doi: 10.1212/WNL.0b013e3182477ec0
pubmed: 22262741
pmcid: 3466608
Rocha MS, Andrade LA, Ferraz HB, Borges V (1995) Levodopa-induced dyskinesia in 176 patients with Parkinson’s disease. Arq Neuropsiquiatr 53:737–742
doi: 10.1590/S0004-282X1995000500004
pubmed: 8729765
Nutt JG (1990) Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 40:340–345. https://doi.org/10.1212/wnl.40.2.340
doi: 10.1212/wnl.40.2.340
pubmed: 2405297
Beaulieu-Boire I, Fasano A (2015) Graft-induced dyskinesias fail to respond to 5HT 1A agonist in the long-term. Mov Disord 30:872–873. https://doi.org/10.1002/mds.26180
doi: 10.1002/mds.26180
pubmed: 25758209
Moro E, Esselink RJA, Benabid AL, Pollak P (2002) Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 125:2408–2417. https://doi.org/10.1093/brain/awf249
doi: 10.1093/brain/awf249
pubmed: 12390968
Lovera LC, Rodriguez-Porcel F, Urrea-Mendoza E, Fasano A, Espay AJ (2016) Flamenco dancer posture. Neurology 86:1462–1463. https://doi.org/10.1212/WNL.0000000000002575
doi: 10.1212/WNL.0000000000002575
pubmed: 27163662
pmcid: 4831036
Růžička E, Zárubová K, Nutt JG, Bloem BR (2011) “Silly Walks” in Parkinson’s disease: unusual presentation of dopaminergic-induced dyskinesias. Mov Disord 26:1782–1784. https://doi.org/10.1002/mds.23667
doi: 10.1002/mds.23667
pubmed: 21495073
Lhermitte F, Agid Y, Signoret JL (1978) Onset and end-of-dose levodopa-induced dyskinesias: possible treatment by increasing the daily doses of levodopa. Arch Neurol 35:261–263. https://doi.org/10.1001/archneur.1978.00500290007002
doi: 10.1001/archneur.1978.00500290007002
pubmed: 646679
Metman LV, Espay AJ (2017) Teaching video neuro images: the underrecognized diphasic dyskinesia of Parkinson disease. Neurology 89:e83–e84. https://doi.org/10.1212/WNL.0000000000004238
doi: 10.1212/WNL.0000000000004238
Bhidayasiri R, Tarsy D (2012) Parkinson’s disease: diphasic dyskinesia. In: CNS Drugs. pp 12–13. https://doi.org/10.1007/978-1-60327-426-5_6
Apetauerova D, Ryan RK, Ro SI, Arle J, Shils J, Papavassiliou E, Tarsy D (2006) End of day dyskinesia in advanced Parkinson’s disease can be eliminated by bilateral subthalamic nucleus or globus pallidus deep brain stimulation. Mov Disord 21:1277–1279. https://doi.org/10.1002/mds.20896
doi: 10.1002/mds.20896
pubmed: 16637040
Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, Johnson R, Chernick D, Hubble J (2020) EASE LID 2: a 2-year open-label trial of Gocovri (amantadine) extended release for dyskinesia in Parkinson’s Disease. J Parkinsons Dis 10:543–548. https://doi.org/10.3233/JPD-191841
doi: 10.3233/JPD-191841
pubmed: 31929122
pmcid: 7242830
Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord 22:179–186. https://doi.org/10.1002/mds.21226
doi: 10.1002/mds.21226
pubmed: 17094088
Wictorin K, Widner H (2016) Memantine and reduced time with dyskinesia in Parkinson’s disease. Acta Neurol Scand 133. https://doi.org/10.1111/ane.12468
Lyons KE, Pahwa R (2006) Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 29. https://doi.org/10.1097/01.WNF.0000220814.48360.F4
Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ (2004) Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 75. https://doi.org/10.1136/jnnp.2003.011551
Durif F (1999) Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging 14. https://doi.org/10.2165/00002512-199914050-00002
Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S, Freed C, Eidelberg D (2002) Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 52:628–634. https://doi.org/10.1002/ana.10359
doi: 10.1002/ana.10359
pubmed: 12402261
Nutt JG, Chung KA, Holford NHG (2010) Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 74:1191–1197. https://doi.org/10.1212/WNL.0b013e3181d90050
doi: 10.1212/WNL.0b013e3181d90050
pubmed: 20220120
pmcid: 2865731
Meloni M, Solla P, Mascia MM, Marrosu F, Cannas A (2017) Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson’s disease. Parkinsonism Relat Disord 37:92–96. https://doi.org/10.1016/j.parkreldis.2016.12.030
doi: 10.1016/j.parkreldis.2016.12.030
pubmed: 28063683
Melgari J-M, Salomone G, di Biase L, Marano M, Scrascia F, Di Lazzaro V (2015) Dyskinesias during levodopa–carbidopa intestinal gel (LCIG) infusion: Management inclinical practice. Parkinsonism Relat Disord 21:327–328. https://doi.org/10.1016/j.parkreldis.2014.12.023
doi: 10.1016/j.parkreldis.2014.12.023
pubmed: 25595317
Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O’Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099–1109. https://doi.org/10.1016/S1474-4422(22)00400-8
doi: 10.1016/S1474-4422(22)00400-8
pubmed: 36402160
Espay AJ, Albanese A, Ellenbogen AL, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vera J, Isaacson SH, Kieburtz KD, LeWitt PA, Lopez-Manzanares L, Olanow W, Pahwa R, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Felix-Lopes N, Sasson N, Case RJ, Rascol O, Stocchi F (2023) Efficacy and safety of continuous subcutaneous ND0612 infusion compared with oral immediate-release levodopa-carbidopa in patients with Parkinson’s disease and motor fluctuations. Am Acad Neurol. https://neuroderm.com/our-company/news-and-events/positive-results-from-the-pivotal-phase-iii-boundlesstrial/ . Accessed 18 Nov 2023
Vaamonde J, Luquin MR, Obeso JA (1991) Subcutaneous lisuride infusion in Parkinson’s disease: response to chronic administration in 34 patients. Brain 14:601–617. https://doi.org/10.1093/brain/114.1.601
doi: 10.1093/brain/114.1.601
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759. https://doi.org/10.1016/S1474-4422(18)30239-4
doi: 10.1016/S1474-4422(18)30239-4
pubmed: 30055903
Quinn N, Parkes JD, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131–1131. https://doi.org/10.1212/WNL.34.9.1131
doi: 10.1212/WNL.34.9.1131
pubmed: 6540399